Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 9/20 | 0.52 |
| ▸ | GPR183 | P32249 | 5/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.39 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.39 |
| ▸ | ITGAL | P20701 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1587696 | 1.00 | CCR2 (0.52) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL1587375 | 0.91 | GPR183 (0.53) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL1587372 | 0.91 | GPR183 (0.53) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL1587220 | 0.90 | GPR183 (0.52) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL1587223 | 0.90 | GPR183 (0.52) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL1587711 | 0.90 | GPR183 (0.46) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2896347 | 0.89 | CCR2 (0.58) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL2896343 | 0.89 | CCR2 (0.58) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL1588092 | 0.89 | GPR183 (0.51) | CCR2GPR183SLC2A1NPC1RAB9A | |
| SCHEMBL1588095 | 0.89 | GPR183 (0.51) | CCR2GPR183SLC2A1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491022-B1 | DIAZEPAN DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| US-8445674-B2 | Heterocyclyl compounds | Hoffmann-La Roche Inc (US) | 2013-05-21 | — | — | US | disclosed |
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092698-A1 | NOVEL HETEROCYCLYL COMPOUNDS | CCR2, CCR3, CCR1 | CCR2 1/4885GPR183 95/4885SLC2A1 4116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.